1476-5381/asset/olbannerleft.gif?v=1&s=198ba9e64c782a75183a18cb494f9d10ecc901ea)
1476-5381/asset/olbannerright.gif?v=1&s=0b2124237bd4227e7991f1ea05cd4bed2496a9ae)
You have full text access to this OnlineOpen article
Systemic administration of β2-adrenoceptor agonists, formoterol and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses
Article first published online: 30 JAN 2009
DOI: 10.1038/sj.bjp.0706669
2006 British Pharmacological Society
1476-5381/asset/cover.gif?v=1&s=f56f5a76559ff1cebf2b6e329fe028f1e9e0f463 "British Journal of Pharmacology")
Additional Information
How to Cite
Ryall, J. G., Sillence, M. N. and Lynch, G. S. (2006), Systemic administration of β2-adrenoceptor agonists, formoterol and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses. British Journal of Pharmacology, 147: 587–595. doi: 10.1038/sj.bjp.0706669
Publication History
- Issue published online: 30 JAN 2009
- Article first published online: 30 JAN 2009
- (Received September 21, 2005, Revised October 19, 2005, Accepted October 23, 2005)
- Abstract
- Article
- References
- Cited By
Cited in:
- CrossRef
This article has been cited by:
- 1, , , , , , , , , , , , , Cardiac sympathetic neurons provide trophic signal to the heart via 2-adrenoceptor-dependent regulation of proteolysis, Cardiovascular Research, 2013, 97, 2, 240
- 2, , , , , , , CL316,243, a selective β3-adrenoceptor agonist, activates protein translation through mTOR/p70S6K signaling pathway in rat skeletal muscle cells, Pflügers Archiv - European Journal of Physiology, 2013, 465, 4, 509
- 3, , , , , , , Effect of acute and short-term oral salbutamol treatments on maximal power output in non-asthmatic athletes, European Journal of Applied Physiology, 2012, 112, 9, 3251
- 4, , , , , , , , Lack of β2-AR improves exercise capacity and skeletal muscle oxidative phenotype in mice, Scandinavian Journal of Medicine & Science in Sports, 2012, 22, 6Direct Link:
- 5, , , , , , , , , The 2-Adrenoceptor Agonist Formoterol Improves Structural and Functional Regenerative Capacity of Skeletal Muscles From Aged Rat at the Early Stages of Postinjury, The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 2012, 67A, 5, 443
- 6, , , , , Urocortins Improve Dystrophic Skeletal Muscle Structure and Function through Both PKA- and Epac-Dependent Pathways, The American Journal of Pathology, 2012, 180, 2, 749
- 7
- 8, , Don't ‘agonise’ over the mechanisms underlying β-agonist-induced muscle hypertrophy!, The Journal of Physiology, 2011, 589, 1Direct Link:
- 9, , , Doping and musculoskeletal system: short-term and long-lasting effects of doping agents, Fundamental & Clinical Pharmacology, 2011, 25, 5Direct Link:
- 10, , , , , , , , Effects of Salmeterol on Skeletal Muscle Cells, Medicine & Science in Sports & Exercise, 2011, 43, 12, 2259
- 11, , , , , , , , , Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle, Molecular Genetics and Metabolism, 2011, 103, 2, 107
- 12, , , , Muscle Plasticity and ����-Adrenergic Receptors: Adaptive Responses of ����-Adrenergic Receptor Expression to Muscle Hypertrophy and Atrophy, Journal of Biomedicine and Biotechnology, 2011, 2011, 1
- 13, , , The muscle-hypertrophic effect of clenbuterol is additive to the hypertrophic effect of myostatin suppression, Muscle & Nerve, 2011, 43, 5Direct Link:
- 14, , , , , , , Cellular mechanisms underlying temporal changes in skeletal muscle protein synthesis and breakdown during chronic β-adrenoceptor stimulation in mice, The Journal of Physiology, 2010, 588, 23Direct Link:
- 15, , , , , Making Fast-Twitch Dystrophic Muscles Bigger Protects Them from Contraction Injury and Attenuates the Dystrophic Pathology, The American Journal of Pathology, 2010, 176, 1, 29
- 16, , , , Cardiac cachexia: A systematic overview, Pharmacology & Therapeutics, 2009, 121, 3, 227
- 17, , , Dystrophin glycoprotein complex-associated Gβγ subunits activate phosphatidylinositol-3-kinase/Akt signaling in skeletal muscle in a laminin-dependent manner, Journal of Cellular Physiology, 2009, 219, 2Direct Link:
- 18, , , , The role of β-adrenoceptor signaling in skeletal muscle: therapeutic implications for muscle wasting disorders, Current Opinion in Clinical Nutrition and Metabolic Care, 2009, 12, 6, 601
- 19, , , ANABOLIC AGENTS FOR IMPROVING MUSCLE REGENERATION AND FUNCTION AFTER INJURY, Clinical and Experimental Pharmacology and Physiology, 2008, 35, 7Direct Link:
- 20, , , , , , Cross-Transfer Effects of Resistance Training with Blood Flow Restriction, Medicine & Science in Sports & Exercise, 2008, 40, 2, 258
- 21, , The potential and the pitfalls of β-adrenoceptor agonists for the management of skeletal muscle wasting, Pharmacology & Therapeutics, 2008, 120, 3, 219
- 22, , , The rush to adrenaline: drugs in sport acting on the β-adrenergic system, British Journal of Pharmacology, 2008, 154, 3Direct Link:
- 23, Update on emerging drugs for sarcopenia – age-related muscle wasting, Expert Opinion on Emerging Drugs, 2008, 13, 4, 655
- 24, , , Attenuation of Age-Related Muscle Wasting and Weakness in Rats After Formoterol Treatment: Therapeutic Implications for Sarcopenia, The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 2007, 62, 8, 813
- 25, , , , Duchenne muscular dystrophy: Focus on pharmaceutical and nutritional interventions, The International Journal of Biochemistry & Cell Biology, 2007, 39, 3, 469
- 26, , , , Low dose formoterol administration improves muscle function in dystrophic mdx mice without increasing fatigue, Neuromuscular Disorders, 2007, 17, 1, 47
- 27, , Oxidative stress, chronic disease, and muscle wasting, Muscle & Nerve, 2007, 35, 4Direct Link:
- 28, , , Pharmaceutical treatment of asthma symptoms in elite athletes – doping or therapy?, Scandinavian Journal of Medicine & Science in Sports, 2007, 17, 6Direct Link:
- 29, , , , Targeting systemic inflammation: novel therapies for the treatment of chronic obstructive pulmonary disease, Expert Opinion on Therapeutic Targets, 2007, 11, 10, 1273
- 30, , , Therapeutic approaches for muscle wasting disorders, Pharmacology & Therapeutics, 2007, 113, 3, 461
- 31, , , , Treating systemic effects of COPD, Trends in Pharmacological Sciences, 2007, 28, 10, 544
- 32, , , Cardiac implications for the use of β2-adrenoceptor agonists for the management of muscle wasting, British Journal of Pharmacology, 2006, 147, 6Direct Link: